Cheetah Medical, a Newton, Mass.-based leader in non-invasive hemodynamic monitoring, completed a new $11.76m Series C equity funding round.
Existing investors included MVM Life Science Partners, Springfield Investment Management, Fletcher Spaght Ventures, HighCape Partners, and Robert Bosch Venture Capital.
The company intends to use the funds to expand their commercial presence in the United States.
Led by Chris Hutchison, President and CEO, and Shane Cooke, Chief Strategy Officer, Cheetah Medical provides 100% noninvasive hemodynamic monitoring technologies which are designed for use in critical care, operating room, general care floor, and emergency department settings. The CHEETAH NICOM™ and STARLING™ SV technologies use a proprietary algorithm to provide accurate and precise data, enabling clinicians to quickly see a patient’s full hemodynamic profile.